These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16530700)

  • 21. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
    Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
    Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
    Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
    Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raptor-rictor axis in TGFbeta-induced protein synthesis.
    Das F; Ghosh-Choudhury N; Mahimainathan L; Venkatesan B; Feliers D; Riley DJ; Kasinath BS; Choudhury GG
    Cell Signal; 2008 Feb; 20(2):409-23. PubMed ID: 18068336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapamycin: something old, something new, sometimes borrowed and now renewed.
    Hartford CM; Ratain MJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):381-8. PubMed ID: 17728765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting mTOR signaling in lung cancer.
    Marinov M; Fischer B; Arcaro A
    Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
    Miyazawa M; Yasuda M; Fujita M; Kajiwara H; Hirabayashi K; Takekoshi S; Hirasawa T; Murakami M; Ogane N; Kiguchi K; Ishiwata I; Mikami M; Osamura RY
    Pathol Int; 2009 Jan; 59(1):19-27. PubMed ID: 19121088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O; Almazan G
    J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting mTOR: something old, something new.
    Garber K
    J Natl Cancer Inst; 2009 Mar; 101(5):288-90. PubMed ID: 19244168
    [No Abstract]   [Full Text] [Related]  

  • 34. Enhancing mTOR-targeted cancer therapy.
    Wang X; Sun SY
    Expert Opin Ther Targets; 2009 Oct; 13(10):1193-203. PubMed ID: 19694499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTOR and cancer: reason for dancing at the crossroads?
    Thomas GV
    Curr Opin Genet Dev; 2006 Feb; 16(1):78-84. PubMed ID: 16359855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Dr O'Reilly-Shah et al.
    Rothman BS; Gupta RK; McEvoy MD
    Anesth Analg; 2017 Oct; 125(4):1416-1417. PubMed ID: 28806205
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to D. O'Reilly et al.
    Patel A; Gupta VG; Biswas B; Ganguly S; Das CK; Batra A; Bhethanabhotla S
    JCO Glob Oncol; 2021 Apr; 7():648. PubMed ID: 33956500
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to Wang et al.: Secreted protein kinases?
    Tagliabracci VS; Pinna LA; Dixon JE
    Trends Biochem Sci; 2013 Sep; 38(9):425. PubMed ID: 23992948
    [No Abstract]   [Full Text] [Related]  

  • 39. O'Reilly 's "Greenland".
    Murdoch J
    Science; 1889 Feb; 13(316):150-1. PubMed ID: 17739096
    [No Abstract]   [Full Text] [Related]  

  • 40. News and Notes: Compiled by Robert Calder and Jean O'Reilly.
    Addiction; 2019 Dec; 114(12):2281-2288. PubMed ID: 31650639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.